Alcohol and Alcoholism

Alcohol use disorder (AUD) is characterized by impaired inhibitory control, which plays a role in the continued consumption of alcohol and relapse despite harmful consequences. External environmental cues, such as alcohol-related advertisements, can aggravate cravings and influence drinking behavior; however, their impact on cognitive processes, including inhibitory control, remains unclear.

Grocery stores are creating opportunities, such as a separate bar area and including beer and wine tasting events, to create a unique experience that caters to particular groups of clientele to encourage drinking.

Gabapentin is an anticonvulsant medication approved by the United States Food and Drug Administration (FDA) for the treatment of partial epileptic seizures and for postherpetic neuralgia. Gabapentin’s mechanism of action is as a calcium channel–aminobutyric acid modulator and has been available as a generic medication since 2004. Unlike medications for alcohol use disorder (AUD) with anticraving properties, such as naltrexone (Hendershot et al. 2017) and topiramate (Guglielmo et al.

Hazardous alcohol use poses an increasing public health issue worldwide and it manifests as excessive consumption (acute or chronic), which may lead to addiction. The risk of alcohol-related pathologies correlates with the patterns of intake and increases with the amount of alcohol consumed. While the effects of alcohol consumption on ischemic stroke and ischemic heart disease are well documented, the impact on venous thromboembolism is less clear.

PDF Split View Sebastian T Tong, Michael Gottlieb, Imtiaz Ebna Mannan, Zihan Zheng, Manisha Sinha, Michelle Santangelo, Kristyn Gatling, Efrat Kean, Phillip Watts, Ralph Wang, Juan Carlos Montoy, Ahamed Idris, Samuel MacDonald, Ryan Huebinger, Mandy Hill, Kelli N O’Laughlin, Nicole L Gentile, Jocelyn Dorney, Caitlin Malicki, Joann G Elmore, Kate Diaz Roldan, Gary Chan, Zhenqiu Lin, Robert A Weinstein, Kari A Stephens, Association of binge alcohol use with functional outcomes among individuals...

Jonathan K Noel, Steve Jacob, Samantha K Borden, Kelsey A Gately, Samantha R Rosenthal, Method of accessing alcohol and binge drinking status in youth and young adults, Alcohol and Alcoholism, Volume 60, Issue 1, January 2025, agae087, https://doi.org/10.1093/alcalc/agae087 Close You do not currently have access to this article.

Excessive alcohol consumption contributes to over 3 million deaths worldwide and is associated with over 25% of cirrhosis deaths globally (Moon et al. 2020; Huang et al. 2023). Rates of alcohol consumption and alcohol use disorder (AUD), defined as a pattern of alcohol use leading to clinically significant impairment or distress, continue to rise globally (Manthey et al. 2019).

This study examined differential changes in alcohol use during the COVID-19 pandemic among adults with unhealthy alcohol use. Among 62 924 adults identified with unhealthy alcohol use in primary care prepandemic (1 January 2019 to 29 February 2020), changes in alcohol use during the pandemic (1 March 2020 to 30 June 2022) were examined using electronic health record data from Kaiser Permanente Northern California.

The modest efficacy of naltrexone and other Food & Drug Administration (FDA)-approved medications for alcohol use disorder (AUD) (McPheeters et al. 2023) and their disappointingly low utilization in clinical practice (Ehrie et al. 2020) argue for continued efforts to develop more effective pharmacotherapies for AUD (Litten et al. 2020).

This is a correction to: Sophie Leclercq, 2023 ESBRA Nordmann Award Lecture: Involvement of the gut microbiome-brain axis in alcohol use disorder, Alcohol and Alcoholism, Volume 59, Issue 5, September 2024, agae050, https://doi.org/10.1093/alcalc/agae050 In the originally published version of this manuscript, the title required correction and was given as follows: “Involvement of the gut microbiome-brain axis in alcohol use disorder”.